GNAQ and cancer: BIM-46174 is a selective inhibitor of heterotrimeric G-protein complex, preventing the heterotrimeric G-protein signaling linked to several GPCRs mediating (a) cyclic AMP generation (Gαs), (b) calcium release (Gαq), and (c) cancer cell invasion by Wnt-2 frizzled receptors and high-affinity neurotensin receptors (Gαoi and Gαq).